X0306 4 2018-07-24 1 0001737953 Replimune Group, Inc. REPL 0001703031 Bain Capital Life Sciences Investors, LLC 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001703030 Bain Capital Life Sciences Partners, LP 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001687968 Bain Capital Life Sciences Fund, L.P. 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001702921 BCIP Life Sciences Associates, LP 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001702957 Schwartz Jeffrey Lawrence 200 CLARENDON STREET BOSTON MA 02116 0 0 1 0 0001578965 Koppel Adam C/O BAIN CAPITAL LIFE SCIENCES INVESTORS 200 CLARENDON STREET BOSTON MA 02116 1 0 0 0 Common Stock 2018-07-24 4 C 0 2338968 A 2338968 I See Footnotes Common Stock 2018-07-24 4 P 0 500000 15.00 A 2838968 I See Footnotes Series B Convertible Preferred Stock 2018-07-24 4 C 0 235146 D Common Stock 2338968 0 I See footnotes Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities"). The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date. On July 24, 2018, the Bain Life Sciences Entities purchased, in aggregate, 500,000 shares of Common Stock of the Issuer at a price of $15 per share, pursuant to an underwritten public offering. BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, By: /s/ Adam Koppel, Name: Adam Koppel, Title: Managing Director 2018-07-26 BAIN CAPITAL LIFE SCIENCES PARTNERS, LP, By: Bain Capital Life Sciences Investors, LLC, its general partner, By: /s/ Adam Koppel, Name: Adam Koppel, Title: Managing Director 2018-07-26 BAIN CAPITAL LIFE SCIENCES FUND, L.P., By: Bain Capital Life Sciences Partners, LP, its general partner, By: Bain Capital Life Sciences Investors, LLC, its general partner, By: /s/ Adam Koppel, Name: Adam Koppel, Title: Managing Director 2018-07-26 BCIP LIFE SCIENCES ASSOCIATES, LP, By: Boylston Coinvestors, LLC, its general partner, By: /s/ Adam Koppel, Name: Adam Koppel, Title: Authorized Signatory 2018-07-26 /s/ Jeffrey Schwartz 2018-07-26 /s/ Adam Koppel 2018-07-26